PYK2/FAK inhibitors reverse hypoxia-induced drug resistance in multiple myeloma.
作者信息
Muz Barbara, Buggio Maurizio, Azab Feda, de la Puente Pilar, Fiala Mark, Padval Mahesh V, Weaver David T, Pachter Jonathan A, Vij Ravi, Azab Abdel Kareem
机构信息
Department of Radiation Oncology, Cancer Biology Division, Washington University in Saint Louis School of Medicine, Saint Louis, MO, USA.
Nanomedicine Laboratory, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.
出版信息
Haematologica. 2019 Jul;104(7):e310-e313. doi: 10.3324/haematol.2018.194688. Epub 2019 Jan 17.
Abstract
摘要
相似文献
1
PYK2/FAK inhibitors reverse hypoxia-induced drug resistance in multiple myeloma.PYK2/FAK抑制剂可逆转缺氧诱导的多发性骨髓瘤耐药性。
Haematologica. 2019 Jul;104(7):e310-e313. doi: 10.3324/haematol.2018.194688. Epub 2019 Jan 17.
2
Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma.黏着斑激酶：胰腺癌和恶性胸膜间皮瘤的潜在治疗靶点。
Cancer Biol Ther. 2018 Apr 3;19(4):316-327. doi: 10.1080/15384047.2017.1416937. Epub 2018 Feb 22.
3
Pyk2 promotes tumor progression in multiple myeloma.Pyk2促进多发性骨髓瘤的肿瘤进展。
Blood. 2014 Oct 23;124(17):2675-86. doi: 10.1182/blood-2014-03-563981. Epub 2014 Sep 12.
4
Addressing Kinase-Independent Functions of Fak via PROTAC-Mediated Degradation.通过 PROTAC 介导的降解来解决 Fak 的激酶非依赖性功能。
J Am Chem Soc. 2018 Dec 12;140(49):17019-17026. doi: 10.1021/jacs.8b08008. Epub 2018 Nov 28.
5
Focal adhesion kinase-related proline-rich tyrosine kinase 2 and focal adhesion kinase are co-overexpressed in early-stage and invasive ErbB-2-positive breast cancer and cooperate for breast cancer cell tumorigenesis and invasiveness.粘着斑激酶相关富含脯氨酸的酪氨酸激酶2和粘着斑激酶在早期及侵袭性ErbB-2阳性乳腺癌中共同过表达，并协同促进乳腺癌细胞的肿瘤发生和侵袭性。
Am J Pathol. 2008 Nov;173(5):1540-50. doi: 10.2353/ajpath.2008.080292. Epub 2008 Oct 2.
6
Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer.粘着斑激酶抑制剂VS-6063（地法替尼）对多西他赛治疗前列腺癌疗效的影响。
Prostate. 2018 Mar;78(4):308-317. doi: 10.1002/pros.23476. Epub 2018 Jan 5.
7
Targeting PYK2 mediates microenvironment-specific cell death in multiple myeloma.靶向PYK2可介导多发性骨髓瘤中微环境特异性细胞死亡。
Oncogene. 2016 May;35(21):2723-34. doi: 10.1038/onc.2015.334. Epub 2015 Sep 21.
8
Selective targeting of FAK-Pyk2 axis by alpha-naphthoflavone abrogates doxorubicin resistance in breast cancer cells.通过α-萘黄酮靶向 FAK-Pyk2 轴可消除乳腺癌细胞对阿霉素的耐药性。
Cancer Lett. 2015 Jun 28;362(1):25-35. doi: 10.1016/j.canlet.2015.03.009. Epub 2015 Mar 18.
9
Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors.靶向胰腺神经内分泌肿瘤中的粘着斑激酶及对mTOR抑制的抗性
J Natl Cancer Inst. 2015 May 12;107(8). doi: 10.1093/jnci/djv123. Print 2015 Aug.
引用本文的文献
1
Focal adhesion kinase as a new player in the biology of onco-hematological diseases: the starting evidence.粘着斑激酶作为血液肿瘤疾病生物学中的新角色：初步证据
Front Oncol. 2024 Aug 30;14:1446723. doi: 10.3389/fonc.2024.1446723. eCollection 2024.
2
IL-10R inhibition reprograms tumor-associated macrophages and reverses drug resistance in multiple myeloma.白细胞介素-10 受体抑制作用可重塑肿瘤相关巨噬细胞，并逆转多发性骨髓瘤的耐药性。
Leukemia. 2024 Nov;38(11):2355-2365. doi: 10.1038/s41375-024-02391-8. Epub 2024 Aug 30.
3
Bone marrow stromal cells induce chromatin remodeling in multiple myeloma cells leading to transcriptional changes.骨髓基质细胞诱导多发性骨髓瘤细胞中的染色质重塑，导致转录变化。
Nat Commun. 2024 May 16;15(1):4139. doi: 10.1038/s41467-024-47793-5.
4
PYK2 is overexpressed in chronic lymphocytic leukaemia: A potential new therapeutic target.PYK2 在慢性淋巴细胞白血病中过表达：一个潜在的新治疗靶点。
J Cell Mol Med. 2023 Feb;27(4):576-586. doi: 10.1111/jcmm.17688. Epub 2023 Feb 6.
5
Systematic Identification of Genomic Markers for Guiding Iron Oxide Nanoparticles in Cervical Cancer Based on Translational Bioinformatics.基于转化生物信息学的宫颈癌导向氧化铁纳米颗粒的基因组标志物的系统鉴定。
Int J Nanomedicine. 2022 Jun 29;17:2823-2841. doi: 10.2147/IJN.S361483. eCollection 2022.
6
Focal adhesion kinase inhibitors, a heavy punch to cancer.粘着斑激酶抑制剂，对癌症的有力一击。
Discov Oncol. 2021 Nov 22;12(1):52. doi: 10.1007/s12672-021-00449-y.
7
A pilot study of 3D tissue-engineered bone marrow culture as a tool to predict patient response to therapy in multiple myeloma.三维组织工程骨髓培养作为预测多发性骨髓瘤患者对治疗反应的工具的初步研究。
Sci Rep. 2021 Sep 29;11(1):19343. doi: 10.1038/s41598-021-98760-9.
8
Circular RNA Protein Tyrosine Kinase 2 Promotes Cell Proliferation, Migration and Suppresses Apoptosis Activating MicroRNA-638 Mediated MEK/ERK, WNT/β-Catenin Signaling Pathways in Multiple Myeloma.环状RNA蛋白酪氨酸激酶2通过激活微小RNA-638介导的MEK/ERK、WNT/β-连环蛋白信号通路促进多发性骨髓瘤细胞增殖、迁移并抑制凋亡
Front Oncol. 2021 Jul 28;11:648189. doi: 10.3389/fonc.2021.648189. eCollection 2021.
9
Reporters of Cancer Stem Cells as a Tool for Drug Discovery.癌症干细胞作为药物发现工具的报道。
Front Oncol. 2021 Apr 22;11:669250. doi: 10.3389/fonc.2021.669250. eCollection 2021.
10
Targeting of the COX-2/PGE2 axis enhances the antitumor activity of T7 peptide and .靶向 COX-2/PGE2 轴增强了 T7 肽和 的抗肿瘤活性。
Drug Deliv. 2021 Dec;28(1):844-855. doi: 10.1080/10717544.2021.1914776.
本文引用的文献
1
Tariquidar sensitizes multiple myeloma cells to proteasome inhibitors via reduction of hypoxia-induced P-gp-mediated drug resistance.塔里喹达通过降低缺氧诱导的P-糖蛋白介导的耐药性，使多发性骨髓瘤细胞对蛋白酶体抑制剂敏感。
Leuk Lymphoma. 2017 Dec;58(12):2916-2925. doi: 10.1080/10428194.2017.1319052. Epub 2017 May 16.
2
Direct measurement of hypoxia in a xenograft multiple myeloma model by optical-resolution photoacoustic microscopy.通过光学分辨率光声显微镜直接测量异种移植多发性骨髓瘤模型中的缺氧情况。
Cancer Biol Ther. 2017 Feb;18(2):101-105. doi: 10.1080/15384047.2016.1276137. Epub 2017 Jan 3.
3
Inhibition of P-Selectin and PSGL-1 Using Humanized Monoclonal Antibodies Increases the Sensitivity of Multiple Myeloma Cells to Bortezomib.使用人源化单克隆抗体抑制P-选择素和PSGL-1可增加多发性骨髓瘤细胞对硼替佐米的敏感性。
Biomed Res Int. 2015;2015:417586. doi: 10.1155/2015/417586. Epub 2015 Oct 11.
4
3D tissue-engineered bone marrow as a novel model to study pathophysiology and drug resistance in multiple myeloma.3D组织工程化骨髓作为研究多发性骨髓瘤病理生理学和耐药性的新型模型。
Biomaterials. 2015 Dec;73:70-84. doi: 10.1016/j.biomaterials.2015.09.017. Epub 2015 Sep 12.
5
Targeting PYK2 mediates microenvironment-specific cell death in multiple myeloma.靶向PYK2可介导多发性骨髓瘤中微环境特异性细胞死亡。
Oncogene. 2016 May;35(21):2723-34. doi: 10.1038/onc.2015.334. Epub 2015 Sep 21.
6
Hypoxia promotes stem cell-like phenotype in multiple myeloma cells.缺氧促进多发性骨髓瘤细胞中的干细胞样表型。
Blood Cancer J. 2014 Dec 5;4(12):e262. doi: 10.1038/bcj.2014.82.
7
Pyk2 promotes tumor progression in multiple myeloma.Pyk2促进多发性骨髓瘤的肿瘤进展。
Blood. 2014 Oct 23;124(17):2675-86. doi: 10.1182/blood-2014-03-563981. Epub 2014 Sep 12.
8
Molecularly targeted therapies in multiple myeloma.多发性骨髓瘤的分子靶向治疗
Leuk Res Treatment. 2014;2014:976567. doi: 10.1155/2014/976567. Epub 2014 Apr 16.
9
Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients.多发性骨髓瘤患者的生存率持续提高：老年患者早期死亡率和结局的变化。
Leukemia. 2014 May;28(5):1122-8. doi: 10.1038/leu.2013.313. Epub 2013 Oct 25.
10
Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features.缺氧通过获得上皮间质转化样特征促进多发性骨髓瘤的扩散。
Blood. 2012 Jun 14;119(24):5782-94. doi: 10.1182/blood-2011-09-380410. Epub 2012 Mar 6.
Zotero 插件